웨어러블 의료기기 소프트웨어 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the wearable medical device software market size is projected to be USD 8.44 billion in 2025, USD 10.40 billion in 2026, and reach USD 31.59 billion by 2031, growing at a CAGR of 24.88% from 2026 to 2031.

This report is Segmented by Component (Software, Services), Device Type (Smartwatches, Patches, ECG Monitors, CGM Devices, Hearables), Application (RPM, Chronic Disease, Fitness), End User (Hospitals, Home Care, Consumers), Deployment (Cloud, Hybrid, On-Prem), Functionality (Monitoring, CDS), Connectivity (Bluetooth, Hybrid), and Geography (North America, Europe, APAC, MEA, South America).

Global Wearable Medical Device Software Market Trends and Insights

Rising Demand For Remote Patient Monitoring Redefines Care Economics

The wearable medical device software market is moving further toward continuous monitoring, because providers now need ongoing patient visibility instead of isolated readings collected during facility visits. Remote patient monitoring accounted for 27.6% of the application segment in 2025, which shows that the installed base is already large enough to support recurring software revenue rather than one-time device sales. This shift matters because software platforms manage data capture, alerts, reporting, and patient communication across episodes of care, while the underlying hardware is becoming less differentiated over time. Consumer wellness demand is also feeding this transition, but the stronger commercial signal comes from care programs that use wearable data inside structured clinical workflows. As a result, the wearable medical device software market is increasingly rewarding vendors that can support continuous care at scale without adding friction for clinicians or patients.

Expansion Of Chronic Disease Management Programs Drives Sustained Software Spend

The wearable medical device software market is benefiting from chronic disease programs that now place measurable value on continuous monitoring for diabetes, chronic kidney disease, cardiovascular disease, musculoskeletal pain, and behavioral health. The CMS ACCESS Model began enrolling Medicare beneficiaries on July 5, 2026, and its payment design ties reimbursement to patient outcomes rather than service volume, which changes how providers evaluate wearable software investments. That structure makes software more central to care delivery, because health systems need tools that can surface deterioration early, guide intervention timing, and document patient progress over time. It also strengthens long-term demand, since chronic disease programs require ongoing engagement, stable data flows, and strong reporting discipline rather than short usage cycles. The wearable medical device software market therefore stands to gain from care models that treat software as a clinical operating layer instead of a support tool.

Alert Fatigue And Workflow Disruption Constrain Clinical Adoption

The wearable medical device software market still faces a serious adoption barrier in the form of alert fatigue, especially in high-volume monitoring programs where threshold-based systems generate too many low-value notifications. A 2026 study of NHS remote patient monitoring deployments reported false positive alert rates of 74% to 99%, which contributed to clinical desensitization and weaker response quality over time. When care teams receive more alerts than they can reasonably triage, extra monitoring data stops creating value and can even raise legal and operational risk. Vendors are responding by introducing patient-specific baselines and probability-based scoring, but health systems still have to decide how much model risk they are willing to accept. The wearable medical device software market will keep facing resistance in large deployments until software can reduce noise without missing clinically important deterioration signals.

Other drivers and restraints analyzed in the detailed report include:

1. Integration Of AI-Enabled Alerting And Risk Scoring Unlocks Clinical Utility
2. Growth In Reimbursement And Value-Based Care Adoption Accelerates Market Entry
3. Data Privacy, Security, And Consent Compliance Burden Introduces Structural Cost

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Software accounted for 78.2% of the segment in 2025, which shows that the wearable medical device software market is already centered on applications, analytics, middleware, and data management rather than on hardware alone. This concentration reflects a broad shift in value capture, where sensors and form factors are becoming easier to replicate but clinical interpretation and workflow integration remain harder to commoditize. Mobile applications, visualization tools, device management layers, integration software, and data platforms are no longer acting as separate point tools in many deployments. Instead, buyers increasingly prefer integrated stacks that can collect data, analyze it, route it into care systems, and support patient engagement from a single environment. Software held 78.2% of the wearable medical device software market share in 2025, which underlines how much of the category's economics now depend on recurring digital functionality rather than device replacement cycles.

Services made up the remaining portion of the segment and continue to benefit from implementation complexity, especially when enterprise deployments span more than one EHR or care platform. Support and maintenance remain relevant because clinical monitoring programs cannot tolerate interrupted connectivity, unstable reporting, or incomplete patient records across care teams. Training and consulting also remain important, since clinician adoption often depends on workflow design, escalation rules, and clear user responsibilities rather than technology alone. The middleware layer is especially important in the wearable medical device software industry because provider systems increasingly expect standardized data exchange that can fit into existing digital records. VitalConnect's USD 100 million financing in February 2025 reinforced that investors still see durable revenue potential in software-led wearable monitoring platforms that combine biosensors, analytics, and cloud delivery.

Smartwatches held 31.2% of the device type segment in 2025, and their lead reflects both a large installed base and wider clinical acceptance for ECG, blood oxygen, activity, and related monitoring functions. That installed base gives software vendors a broad distribution channel, because many users already carry the hardware needed for basic digital monitoring. The wearable medical device software market continues to benefit from this dynamic because smartwatch software can scale quickly when new features are accepted by consumers and providers at the same time. At the same time, device credibility matters, and that favors platforms with clinically meaningful outputs rather than simple wellness tracking. Smartwatches remain the largest category, but the strongest expansion is occurring where continuous sensor data supports higher clinical relevance and more frequent intervention.

CGM software-enabled devices are projected to grow at a 26.2% CAGR through 2031, and that pace reflects stronger links between data capture, algorithmic interpretation, and treatment action. Diabeloop's DBLG2 system, which received CE marking in August 2025 and FDA clearance in December 2025, launched commercially in Germany in July 2026 and reported real-world Time in Range above 77% in Kaleido user data. Patches, standalone ECG monitors, smart bands, smart clothing, and hearables still serve important clinical niches, particularly in arrhythmia detection, low-burden wear, and specialty monitoring. The 2025 scientific literature also supports the strength of CGM-led software, since 70% of published AI wearable diabetes studies relied on CGM as the primary sensing modality. In practical terms, the wearable medical device software market is seeing device leadership shift toward categories where software can influence decisions, not just display readings.

Remote patient monitoring accounted for 27.6% of the application segment in 2025, which makes it the largest current use case in the wearable medical device software market. That position reflects clear provider demand for continuous low-acuity monitoring that can reduce unnecessary hospital visits, extend oversight beyond clinics, and support earlier escalation when risk rises. RPM also fits well with the software-first structure of the category, because value depends on data capture, alerts, dashboards, and communication workflows rather than only on device ownership. Remote patient monitoring accounted for 27.6% of wearable medical device software market share in 2025, which confirms that the strongest base of adoption remains tied to organized care delivery. Fitness and wellness monitoring still generates meaningful volume, but clinical monetization remains narrower when outputs do not connect to validated care pathways or reimbursable programs.

Chronic disease management is forecast to grow at a 26.1% CAGR through 2031, and that strength is closely tied to conditions where repeated measurements directly influence long-term care plans. The CMS ACCESS Model covers diabetes, chronic kidney disease, cardiovascular disease, musculoskeletal pain, and behavioral health, which aligns closely with the kinds of patient journeys where wearable software can influence outcomes over time. Post-acute care monitoring is also gaining traction as health systems try to reduce readmissions after discharge, while medication adherence and sleep or stress tracking are finding broader relevance in behavioral health settings. AI-enabled glucose forecasting adds another layer of value here, because predictive models can move software from retrospective logging toward prospective intervention. The wearable medical device software market therefore shows its strongest application growth where monitoring becomes part of a longitudinal care model rather than a standalone data service.

Complete Report Scope:

• By Component
  • Hardware
  • Software
  • Services
• By Deployment Mode
  • Conventional AI-Enhanced CT
  • Spectral CT
  • Photon-Counting CT
  • Interventional CT
• By Application
  • Oncology Diagnosis and Staging
  • Tumor Monitoring and Treatment Response
  • Radiation Therapy Planning Support
  • Research and Clinical Trials
• By End User
  • Hospitals
  • Diagnostic Imaging Centers
  • Cancer Treatment Centers
  • Academic and Research Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.1% of the geographic segment in 2025, which made it the largest regional block in the wearable medical device software market. The United States anchors that position because it combines large payer capacity, structured digital health reimbursement pathways, and broad provider readiness for remote monitoring. The CMS ACCESS Model has strengthened this environment by tying payment to outcomes in chronic care categories that align closely with wearable monitoring use cases. Canada and Mexico remain smaller contributors, but both continue to expand hospital-based remote monitoring adoption as digital care capabilities widen. North America represented 39.1% of the wearable medical device software market size in 2025, and that scale gives vendors room to balance enterprise contracts with direct user subscription models.

Europe holds the second-largest regional position in the wearable medical device software market, with Germany, the United Kingdom, and France acting as the primary country markets. Germany stands out because the DiGA pathway offers a faster route for digital health applications to reach reimbursable use, which supports commercial experimentation and software uptake. Diabeloop's July 2026 commercial launch of the DBLG2 system in Germany illustrates how regulatory compliance and commercialization can reinforce one another when clinical data is strong. The United Kingdom continues to expand trust-level remote monitoring programs, but the high false positive alert rates reported in NHS deployments show that software quality still shapes procurement choices. Across Europe, GDPR obligations for sensitive health data continue to influence cloud design, consent handling, and cross-border operating models.

Asia Pacific is projected to grow at a 26.2% CAGR through 2031, which makes it the fastest-growing regional segment in the wearable medical device software market. Growth is being supported by a large chronic disease burden, rising digital health investment, and stronger government involvement in healthcare modernization across major markets. Japan is tightening expectations around software validation for biosensor-linked products, while South Korea is expanding digital health infrastructure and China is pushing international vendors toward more localized strategies. The Middle East and Africa, led by GCC countries, and South America, led by Brazil and Argentina, remain earlier-stage regions where adoption is more concentrated in private healthcare and premium consumer channels, but both are positioned to benefit as connectivity expands and wearable hardware becomes more affordable.

1. Alphabet Inc. (Google Health / DeepMind)
2. Microsoft
3. NVIDIA
4. Siemens Healthineers
5. GE HealthCare Technologies Inc.
6. Koninklijke Philips
7. Roche
8. Tempus AI, Inc.
9. Aidoc Medical Ltd.
10. Qure.ai Technologies Private Limited
11. Heartflow
12. PathAI, Inc.
13. Paige.AI, Inc.
14. Ada Health GmbH
15. AliveCor
16. Butterfly Network, Inc.
17. Digital Diagnostics
18. Lunit
19. Ibex Medical Analytics Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Oncology Imaging Demand
  • 4.2.2 AI Assisted Protocol Optimization
  • 4.2.3 Photon Counting and Spectral Precision Gains
  • 4.2.4 Radiation Dose Reduction Pressure
  • 4.2.5 Oncology Workflow Automation and Triage
  • 4.2.6 Reimbursement Support for Quantitative Imaging
• 4.3 Market Restraints
  • 4.3.1 High Capital Cost of Premium CT Platforms
  • 4.3.2 Integration Burden Across PACS, RIS, and EHR Environments
  • 4.3.3 Clinical Validation and Regulatory Friction for AI Features
  • 4.3.4 Cybersecurity and Data Governance Concerns
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces

5 Market Size & Growth Forecasts

• 5.1 By Component
  • 5.1.1 Hardware
  • 5.1.2 Software
  • 5.1.3 Services
• 5.2 By Deployment Mode
  • 5.2.1 Conventional AI-Enhanced CT
  • 5.2.2 Spectral CT
  • 5.2.3 Photon-Counting CT
  • 5.2.4 Interventional CT
• 5.3 By Application
  • 5.3.1 Oncology Diagnosis and Staging
  • 5.3.2 Tumor Monitoring and Treatment Response
  • 5.3.3 Radiation Therapy Planning Support
  • 5.3.4 Research and Clinical Trials
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Diagnostic Imaging Centers
  • 5.4.3 Cancer Treatment Centers
  • 5.4.4 Academic and Research Institutes
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 Alphabet Inc. (Google Health / DeepMind)
  • 6.3.2 Microsoft Corporation
  • 6.3.3 NVIDIA Corporation
  • 6.3.4 Siemens Healthineers AG
  • 6.3.5 GE HealthCare Technologies Inc.
  • 6.3.6 Koninklijke Philips N.V.
  • 6.3.7 F. Hoffmann-La Roche Ltd
  • 6.3.8 Tempus AI, Inc.
  • 6.3.9 Aidoc Medical Ltd.
  • 6.3.10 Qure.ai Technologies Private Limited
  • 6.3.11 Heartflow, Inc.
  • 6.3.12 PathAI, Inc.
  • 6.3.13 Paige.AI, Inc.
  • 6.3.14 Ada Health GmbH
  • 6.3.15 AliveCor, Inc.
  • 6.3.16 Butterfly Network, Inc.
  • 6.3.17 Digital Diagnostics, Inc.
  • 6.3.18 Lunit Inc.
  • 6.3.19 Ibex Medical Analytics Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White Space and Unmet Need Assessment